Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients.
Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-24-0428. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38709212
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorrakrai K, Utro F, Levovitz C, Denault E, Walmsley CS, Kambadakone A, Stone JR, Isakoff SJ, Parida L, Juric D, Getz G, Bardia A, Ellisen LW.
Coates JT, et al. Among authors: thimmiah n.
Cancer Discov. 2021 Oct;11(10):2436-2445. doi: 10.1158/2159-8290.CD-21-0702. Epub 2021 Aug 17.
Cancer Discov. 2021.
PMID: 34404686
Free PMC article.
Item in Clipboard
Cite
Cite